Dynavax Technologies Corp (NASDAQ:DVAX)

CAPS Rating: 2 out of 5

A biopharmaceutical company that discovers and develops Toll-like Receptor 9 and agonist-based products to treat and prevent infectious diseases, allergies, cancer and chronic inflammatory.

Recs

0
Player Avatar pchop123 (78.31) Submitted: 9/6/2012 10:32:34 AM : Underperform Start Price: $4.13 DVAX Score: -6.78

may be running out of upside whil while waiting for next approval

Featured Broker Partners


Advertisement